GOSS - NASDAQ: GOSS Investor Notice: Lawsuit against Gossamer Bio Inc. announced by Shareholders Foundation
SAN DIEGO, April 08, 2020 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Gossamer Bio, Inc. (NASDAQ: GOSS).
Investors, who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The plaintiff alleges that certain materials supporting Gossamer's initial public offering ("IPO"), and certain of Gossamer’s post-IPO public filings, misled investors or otherwise omitted material facts relevant to Gossamer’s GB001 drug and its related clinical trials and studies.
More specifically, the plaintiff alleges that the Defendants misrepresented and/or failed to disclose to investors: (1) the reasons for Gossamer's GB001 trial failures; (2) the purported clinical validation of Novartis' oral DP2 antagonist; and (3) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Shares of Gossamer Bio, Inc. (NASDAQ: GOSS) declined from $19.00 per share at its IPO to as low as $7.52 per share on March 18, 2020.
Those who purchased Gossamer Bio, Inc. (NASDAQ: GOSS) shares should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.